Maki Iwahashi

Title: Maki Iwahashi: Innovator in Pharmaceutical Compounds

Introduction

Maki Iwahashi is a notable inventor based in Mishima-gun, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in developing compounds that target various diseases. With a total of 7 patents to his name, Iwahashi's work is recognized for its potential impact on medical treatments.

Latest Patents

Iwahashi's latest patents include an ALXR agonist compound, which provides a compound having ALXR agonist activity. This invention is aimed at preventing and treating ALXR-associated diseases, such as inflammatory bowel disease, autoimmune diseases, chronic inflammatory diseases, asthma, pulmonary fibrosis, atopic dermatitis, ischemia-reperfusion injury, myocardial infarction, and Alzheimer's disease. Another significant patent is a Trk-inhibiting compound, which serves as a drug component for the prophylaxis and therapy of diseases like pain, pruritus, lower urinary tract dysfunction, asthma, allergic rhinitis, inflammatory bowel disease, and Chagas disease.

Career Highlights

Throughout his career, Maki Iwahashi has worked with prominent companies in the pharmaceutical industry, including Ono Pharmaceutical Co., Ltd. and Ono Pharmaceuticals Co., Ltd. His experience in these organizations has contributed to his expertise in drug development and innovation.

Collaborations

Iwahashi has collaborated with notable colleagues, including Kaoru Kobayashi and Fumio Nambu. These partnerships have likely enhanced his research and development efforts in the pharmaceutical sector.

Conclusion

Maki Iwahashi's contributions to pharmaceutical innovations demonstrate his commitment to advancing medical science. His patents reflect a dedication to addressing critical health issues through innovative compounds.